SG11202010953QA - Tetracyclic heteroaryl compounds - Google Patents
Tetracyclic heteroaryl compoundsInfo
- Publication number
- SG11202010953QA SG11202010953QA SG11202010953QA SG11202010953QA SG11202010953QA SG 11202010953Q A SG11202010953Q A SG 11202010953QA SG 11202010953Q A SG11202010953Q A SG 11202010953QA SG 11202010953Q A SG11202010953Q A SG 11202010953QA SG 11202010953Q A SG11202010953Q A SG 11202010953QA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaryl compounds
- tetracyclic heteroaryl
- tetracyclic
- compounds
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668321P | 2018-05-08 | 2018-05-08 | |
| US201862754814P | 2018-11-02 | 2018-11-02 | |
| PCT/EP2019/061754 WO2019215203A1 (en) | 2018-05-08 | 2019-05-07 | Tetracyclic heteroaryl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010953QA true SG11202010953QA (en) | 2020-12-30 |
Family
ID=66484036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010953QA SG11202010953QA (en) | 2018-05-08 | 2019-05-07 | Tetracyclic heteroaryl compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407765B2 (en) |
| EP (1) | EP3790884A1 (en) |
| JP (1) | JP7138724B2 (en) |
| KR (1) | KR20210006948A (en) |
| CN (1) | CN112074520A (en) |
| AU (1) | AU2019267008B2 (en) |
| BR (1) | BR112020021467A2 (en) |
| CA (1) | CA3098261A1 (en) |
| CL (1) | CL2020002866A1 (en) |
| CO (1) | CO2020013564A2 (en) |
| CR (1) | CR20200532A (en) |
| DO (1) | DOP2020000201A (en) |
| EC (1) | ECSP20070854A (en) |
| JO (1) | JOP20200281A1 (en) |
| MA (1) | MA52560A (en) |
| MX (1) | MX2020011910A (en) |
| NI (1) | NI202000078A (en) |
| PE (1) | PE20211795A1 (en) |
| PH (1) | PH12020551870A1 (en) |
| SG (1) | SG11202010953QA (en) |
| TW (1) | TW202012415A (en) |
| UY (1) | UY38221A (en) |
| WO (1) | WO2019215203A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7453989B2 (en) * | 2019-03-05 | 2024-03-21 | アストラゼネカ・アクチエボラーグ | Fused tricyclic compounds useful as anticancer agents |
| KR20220012255A (en) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | Oxaazaquinazoline-7(8H)-ketone compound, preparation method thereof, and pharmaceutical application thereof |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| KR20220109407A (en) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | RAS inhibitors |
| TW202132316A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| HRP20221301T1 (en) * | 2019-12-11 | 2022-12-23 | Eli Lilly And Company | Kras g12c inhibitors |
| TWI799871B (en) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | Tricyclic compound, its preparation method and medical application |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| CN113980032B (en) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | Fused tetracyclic derivative, preparation method thereof and application thereof in medicines |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114685531A (en) * | 2020-12-25 | 2022-07-01 | 武汉誉祥医药科技有限公司 | Tetraheterocyclic compounds, pharmaceutical compositions and uses thereof |
| KR20230145078A (en) * | 2021-02-09 | 2023-10-17 | 제넨테크, 인크. | Tetracyclic oxazepine compounds and uses thereof |
| WO2022188729A1 (en) * | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| EP4310091A1 (en) * | 2021-03-17 | 2024-01-24 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN117083281A (en) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | Pyrimidine heterocyclic compound and application thereof |
| CN116113632A (en) * | 2021-03-30 | 2023-05-12 | 浙江海正药业股份有限公司 | Heterocyclic derivative, preparation method and medical application thereof |
| JP2024513881A (en) * | 2021-04-08 | 2024-03-27 | ジェネンテック， インコーポレイテッド | Oxazepine compounds and their use in the treatment of cancer |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | Ras inhibitors |
| CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
| JP2024522766A (en) * | 2021-06-21 | 2024-06-21 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Fused tetracyclic compounds, their preparation method and their medical applications |
| CA3224284A1 (en) * | 2021-07-02 | 2023-01-05 | Feng Wang | Kras g12d inhibitor and use thereof |
| WO2023001123A1 (en) * | 2021-07-19 | 2023-01-26 | 上海艾力斯医药科技股份有限公司 | New pyridopyrimidine derivative |
| CN117242079A (en) * | 2021-07-23 | 2023-12-15 | 苏州赞荣医药科技有限公司 | KRAS G12D inhibitors and uses thereof |
| TW202315626A (en) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | Pyrimidine-fused cyclic compound and preparation method and use thereof |
| IL309086A (en) | 2021-09-01 | 2024-02-01 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| KR20240070619A (en) * | 2021-09-27 | 2024-05-21 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Polycyclic fused ring derivatives and uses thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| CA3234517A1 (en) | 2021-10-22 | 2023-04-27 | Xin Li | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| WO2023072297A1 (en) * | 2021-11-01 | 2023-05-04 | 江苏恒瑞医药股份有限公司 | Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine |
| WO2023103906A1 (en) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d inhibitor and use in medicine |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| TW202333800A (en) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | Combination of antibody-drug conjugate and rasg12c inhibitor |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN114539073A (en) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | Synthesis method of 3-bromo-2-chloro-4, 6-difluoroaniline |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024031088A1 (en) * | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041621A1 (en) * | 2022-08-25 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024063578A1 (en) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Novel tetraheterocycle compound |
| WO2024063576A1 (en) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Novel quinazoline compound as kras inhibitor |
| WO2024085661A1 (en) * | 2022-10-18 | 2024-04-25 | Ildong Pharmaceutical Co., Ltd. | Novel triheterocyclic compounds |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024120419A1 (en) * | 2022-12-06 | 2024-06-13 | Zai Lab (Shanghai) Co., Ltd. | Fused tetracyclic compounds as kras g12d modulators and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013155223A1 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| MX364438B (en) | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Covalent inhibitors of kras g12c. |
| CN106488910B (en) | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Inhibitors of KRAS G12C |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| JP6789239B2 (en) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Condensation tricyclic inhibitor of KRAS and method of its use |
| JP6869947B2 (en) | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | Use of substituted quinazoline compound and its G12C mutant KRAS, HRAS and / or NRAS protein as an inhibitor |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017087528A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN110036010A (en) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | The inhibitor of KRAS G12C mutain |
| WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| KR102592246B1 (en) | 2016-12-22 | 2023-10-23 | 암젠 인크 | Benzisothiazole, isothiazolo[3,4-B]pyridine, quinazoline, phthalazine, pyrido[2,3-D]pyridazine and Pyrido[2,3-D]pyrimidine derivatives |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573966A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| JOP20190186A1 (en) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | Quinazoline compound |
| CN110603258A (en) | 2017-05-11 | 2019-12-20 | 阿斯利康(瑞典)有限公司 | Heteroaryl compounds that inhibit G12C mutant RAS proteins |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| KR20200010306A (en) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Covalent Inhibitors of KRAS |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| RS64182B1 (en) | 2017-11-15 | 2023-05-31 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| US10597405B2 (en) | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| TW201942115A (en) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
| TW201942116A (en) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | Tetrahydroquinazoline derivatives useful as anticancer agents |
-
2019
- 2019-05-03 TW TW108115329A patent/TW202012415A/en unknown
- 2019-05-07 CA CA3098261A patent/CA3098261A1/en active Pending
- 2019-05-07 US US17/053,400 patent/US11407765B2/en active Active
- 2019-05-07 CR CR20200532A patent/CR20200532A/en unknown
- 2019-05-07 SG SG11202010953QA patent/SG11202010953QA/en unknown
- 2019-05-07 EP EP19723368.7A patent/EP3790884A1/en not_active Withdrawn
- 2019-05-07 KR KR1020207035034A patent/KR20210006948A/en unknown
- 2019-05-07 JP JP2020560800A patent/JP7138724B2/en active Active
- 2019-05-07 MA MA052560A patent/MA52560A/en unknown
- 2019-05-07 CN CN201980030143.8A patent/CN112074520A/en active Pending
- 2019-05-07 AU AU2019267008A patent/AU2019267008B2/en not_active Expired - Fee Related
- 2019-05-07 JO JOP/2020/0281A patent/JOP20200281A1/en unknown
- 2019-05-07 MX MX2020011910A patent/MX2020011910A/en unknown
- 2019-05-07 WO PCT/EP2019/061754 patent/WO2019215203A1/en unknown
- 2019-05-07 PE PE2020001766A patent/PE20211795A1/en unknown
- 2019-05-07 BR BR112020021467-1A patent/BR112020021467A2/en not_active Application Discontinuation
- 2019-05-08 UY UY38221A patent/UY38221A/en not_active Application Discontinuation
-
2020
- 2020-10-28 CO CONC2020/0013564A patent/CO2020013564A2/en unknown
- 2020-11-04 DO DO2020000201A patent/DOP2020000201A/en unknown
- 2020-11-05 PH PH12020551870A patent/PH12020551870A1/en unknown
- 2020-11-05 CL CL2020002866A patent/CL2020002866A1/en unknown
- 2020-11-06 NI NI202000078A patent/NI202000078A/en unknown
- 2020-11-06 EC ECSENADI202070854A patent/ECSP20070854A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI202000078A (en) | 2021-02-16 |
| WO2019215203A1 (en) | 2019-11-14 |
| US20210221823A1 (en) | 2021-07-22 |
| MA52560A (en) | 2021-03-17 |
| CN112074520A (en) | 2020-12-11 |
| US11407765B2 (en) | 2022-08-09 |
| PE20211795A1 (en) | 2021-09-09 |
| CO2020013564A2 (en) | 2020-11-10 |
| AU2019267008A1 (en) | 2021-01-07 |
| DOP2020000201A (en) | 2020-11-30 |
| EP3790884A1 (en) | 2021-03-17 |
| TW202012415A (en) | 2020-04-01 |
| JP7138724B2 (en) | 2022-09-16 |
| CL2020002866A1 (en) | 2021-02-12 |
| BR112020021467A2 (en) | 2021-01-19 |
| JP2021532061A (en) | 2021-11-25 |
| KR20210006948A (en) | 2021-01-19 |
| UY38221A (en) | 2019-10-31 |
| ECSP20070854A (en) | 2020-12-31 |
| JOP20200281A1 (en) | 2020-11-05 |
| MX2020011910A (en) | 2021-01-29 |
| PH12020551870A1 (en) | 2021-07-26 |
| AU2019267008B2 (en) | 2022-02-17 |
| CR20200532A (en) | 2020-12-23 |
| CA3098261A1 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010953QA (en) | Tetracyclic heteroaryl compounds | |
| GB201805174D0 (en) | Compounds | |
| GB201810092D0 (en) | Compounds | |
| GB201801355D0 (en) | Compounds | |
| GB201807924D0 (en) | Compounds | |
| GB201810581D0 (en) | Compounds | |
| ZA202100237B (en) | Tricyclic compounds | |
| GB201814151D0 (en) | Compounds | |
| GB201808093D0 (en) | Compounds | |
| GB201809102D0 (en) | Compounds | |
| IL271687A (en) | Novel spirolactone compounds | |
| GB201817083D0 (en) | Compounds | |
| GB201812382D0 (en) | Compounds | |
| GB201810071D0 (en) | Compounds | |
| GB201803340D0 (en) | Compounds | |
| GB201814167D0 (en) | Compounds | |
| GB201801130D0 (en) | Compounds | |
| GB201801128D0 (en) | Compounds | |
| IL281175A (en) | Bicyclic heteroaryl derivatives | |
| GB201817342D0 (en) | Compounds | |
| GB201817303D0 (en) | Compounds | |
| GB201817292D0 (en) | Compounds | |
| GB201817291D0 (en) | Compounds | |
| GB201816998D0 (en) | Compounds | |
| GB201816665D0 (en) | Compounds |